Fyn related Src family tyrosine kinaseSRC proto-oncogene, non-receptor tyrosine kinaseCalcium/calmodulin dependent protein kinase IDTyrosine kinase non receptor 2Serine/threonine kinase 4Serine/threonine kinase 24Calcium/calmodulin dependent protein kinase II gammaTXK tyrosine kinaseSerine/threonine kinase 10Mitogen-activated protein kinase kinase kinase kinase 5LYN proto-oncogene, Src family tyrosine kinaseFYN proto-oncogene, Src family tyrosine kinaseABL proto-oncogene 1, non-receptor tyrosine kinase
P129
P2176
ABL1 BCR-ABL E255KABL1 BCR-ABL F359VABL1 BCR-ABL M244VABL1 BCR-ABL Y253HABL1 Y253FABL1 BCR-ABL H396RABL1 BCR-ABL E255VABL1 BCR-ABL F359CABL1 BCR-ABL L384Mchr9:g.133748282A>G (ABL1:p.T315A)chr9:g.133748288T>G (ABL1:p.F317V)chr9:g.133748288T>A (ABL1:p.F317I)chr9:g.133748289T>G (ABL1:p.F317C)chr9:g.133748414T>A (ABL1:p.F359I)
P3354
ABL1 BCR-ABL T315IABL1 BCR-ABL E255KABL1 BCR-ABL F317LABL1 BCR-ABL F359VABL1 BCR-ABL M244VABL1 BCR-ABL L248VABL1 BCR-ABL G250EABL1 BCR-ABL Y253HABL1 Y253FABL1 BCR-ABL D276GABL1 BCR-ABL H396RABL1 BCR-ABL F486SABL1 BCR-ABL E255VABL1 BCR-ABL F359CABL1 BCR-ABL L387FABL1 BCR-ABL E355GABL1 L298VABL1 BCR-ABL F311IABL1 BCR-ABL E453QABL1 BCR-ABL F359IABL1 Q300RABL1 BCR-ABL F311LABL1 BCR-ABL N331SABL1 BCR-ABL L364PABL1 BCR-ABL H396PABL1 D421GABL1 BCR-ABL E450VABL1 BCR-ABL E453KABL1 BCR-ABL E453AABL1 BCR-ABL P480AABL1 C475VABL1 N336SABL1 TKD MUTATIONABL1 P-Loop MutationABL1 Non-P-Loop Mutation
P3355
P3781
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase DomainSafety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibPhase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPδ expression and contributes to transformation of breast tumor cells.SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancerAllografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBosutinib for the treatment of chronic myeloid leukemia in chronic phase.Src kinase inhibitors: promising cancer therapeutics?Denosumab--a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts.A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.Treatments for chronic myeloid leukemia: a qualitative systematic review.Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.HPLC-DAD protein kinase inhibitor analysis in human serum.[Characteristics and outcome of chromosomal abnormalities in Ph negative cells of chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors].A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapyBosutinib Inhibits EGFR Activation in Head and Neck CancerMatching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemiaEffects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors
P921
Q21106691-9A18991D-9DD6-4212-9360-D50597DEF4E3Q21109354-446F2EAE-667F-4B80-9597-8773572E653EQ21113540-8E95C3F8-0767-41FB-931A-13872DDD6D3BQ21115284-48350196-8DDC-41D6-A8D0-3DE20341D107Q21116513-29D89E3C-46B1-4C92-A832-038BEF24F59CQ21117407-785E091C-0DBE-475E-A87B-E8623F12796FQ21118356-F8727921-690D-4BF7-B076-4A753186E3D7Q21119231-7EE765CB-E875-4E87-98CF-BA793E973050Q21127300-C8D0CF00-E3A2-4101-9DAF-13B6461D49F7Q21130085-4108AF47-200E-42B3-9D3D-132C84F38CE9Q2463389-C34C9E62-FE6F-4891-A0C1-1563CBE7629AQ423628-BD5D31A8-C573-4169-A272-368B8D8ABEEBQ587961-5F83CBBB-23E8-4EEB-9AC4-C6D72D2AC6F6
P129
Q27906817-1A8A7543-AEA1-4872-8B9F-B704885799F5Q27906817-CF47D644-994B-4612-A043-32056BBEBB09Q29938345-6820CA04-B12E-4170-A390-81EAC858DCAAQ29938345-75309E28-B5AF-4D4F-9D91-C4B2FC68A78CQ29938509-8035C9E8-2537-4EF1-A22B-2A9078EED2CDQ29938515-C1561199-B1A1-4974-B77A-464783BE1715Q29938516-41D63116-C25D-4D7B-84DC-CE8055401B58Q29938523-5E919692-3EF6-47F4-ADA0-43426DBE578DQ29938702-1C5FBDBC-6587-4002-8C90-D8FE122ABD00Q29938702-78C671CB-CD81-4505-9719-AE78846E3CDEQ29938707-E035A25E-F2EA-45FC-8444-16F33AFEE831Q29938714-F2411D25-953E-44FF-B83F-FAA7D6244351Q38105235-8DAD4432-A6B2-4DDC-A92C-2C80FCE216F8Q38152931-A7E1504C-13DF-4585-A253-E7419095AE44Q38152933-DE6C35EA-2A5F-4E0B-BDBA-011E1AE1B1FCQ38152934-E66420E6-14BB-47BD-99F5-87065E5A8E58Q38153149-44E3CF3F-FC4B-4954-9591-66B627A571C4
P3354
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Bosutinib
@de
Bosutinib
@sh
Bosutinib
@sr
Bosutinib
@vi
bosutinib
@en
bosutinib
@nn
bosutynib
@pl
بوسوتينيب
@ar
ボスチニブ
@ja
波舒替尼
@zh
type
label
Bosutinib
@de
Bosutinib
@sh
Bosutinib
@sr
Bosutinib
@vi
bosutinib
@en
bosutinib
@nn
bosutynib
@pl
بوسوتينيب
@ar
ボスチニブ
@ja
波舒替尼
@zh
altLabel
3-quinolinecarbonitrile, 4-((2 ...... methyl-1-piperazinyl)propoxy)-
@en
4-((2,4-Dichloro-5-methoxyphen ...... opoxy)-3-quinolinecarbonitrile
@en
4-((2,4-dichloro-5-methoxyphen ...... opoxy)-3-quinolinecarbonitrile
@en
4-((2,4-dichloro-5-methoxyphen ...... opoxy)quinoline-3-carbonitrile
@en
Bosulif®
@en
Bosutinib Monohydrate
@en
Bosutinib
@en
SK 606
@en
SK-606
@en
SKI 606
@en
prefLabel
Bosutinib
@de
Bosutinib
@sh
Bosutinib
@sr
Bosutinib
@vi
bosutinib
@en
bosutinib
@nn
bosutynib
@pl
بوسوتينيب
@ar
ボスチニブ
@ja
波舒替尼
@zh